India's drug regulatory body is moving to implement stringent new labeling requirements for cough syrups, proposing prominent red warnings to deter their use in children under four years old. The initiative comes amidst persistent concerns regarding the over-prescription and misuse of these medications in very young children, despite prior health advisories.
New Labeling Requirements Proposed
The proposal, currently under deliberation by the Drugs Consultative Committee, seeks an amendment to Rule 96 of the Drugs Rules, 1945. If approved, cough syrup bottles will feature a clear, red-colored warning stating: "WARNING: Cough syrup should not be used in children below 4 years of age."
Beyond the explicit text, the amendment also suggests including a pictorial depiction of school-age children on the labels. This visual cue is intended to reinforce that the product is suitable for older children, not infants or toddlers, thereby discouraging its administration to younger age groups.
Addressing Persistent Concerns
This regulatory push is a direct response to continued reports of cough syrups being prescribed to infants and young children, even after a Directorate General of Health Services (DGHS) advisory in October 2025. That advisory had specifically recommended against prescribing or dispensing cough and cold medicines to children below two years of age, emphasizing judicious use in pediatric care.
A subsequent complaint highlighted that despite the 2025 directions, the practice of administering these syrups to infants under two had persisted. This prompted an internal technical committee of the Central Drugs Standard Control Organisation (CDSCO) to deliberate the matter in April 2026, recommending discussions with the Indian Council of Medical Research (ICMR) and stakeholder consultations on the feasibility of labeling changes.
Broader Context of Child Safety
While the ICMR indicated it was not actively working on cough syrup labeling, the widespread use of these medicines, both prescribed and over-the-counter, has long been a point of concern among health experts regarding very young children.
The current proposal follows a recent government restriction imposed in August 2022 on all fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride for use in children below four. Manufacturers of these specific combinations were mandated to display a warning on labels, package inserts, and promotional materials. The new, broader cough syrup labeling requirement, if approved, would extend similar protective measures across a wider range of products, signifying a stronger regulatory stance on pediatric medication safety.